Compass Therapeutics Q1 net loss widens on higher R&D, G&A costs

Compass Therapeutics

05/05/2026 12:46

Overview

US oncology biopharma reported Q1 net loss widened yr/yr, R&D and G&A expenses rose

Company ended Q1 with $195 mln in cash and marketable securities, expects runway into 2028

Outlook

Company plans BLA submission for tovecimig in biliary tract cancer later in 2026

Compass expects cash and marketable securities to fund operations into 2028

Result Drivers

R&D SPENDING - Q1 R&D expenses rose 3% yr/yr to $13.4 mln as company advanced multiple clinical studies

PRE-COMMERCIALIZATION COSTS - G&A expenses increased 41% yr/yr to $6.9 mln, driven by pre-commercialization expenses and higher stock compensation

Company press release: ID:nGNX72Zdz0

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Net Income
-$18.32 mln
Q1 Basic EPS
-$0.10
Q1 Income From Operations
-$20.30 mln


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)